PropertyValue
?:abstract
  • The development of therapeutic agents against SARS-CoV-2/COVID-19 faces numerous barriers and a multidisciplinary approach to evaluating drug efficacy and toxicity is essential. Experimental and preclinical data should be integrated into a comprehensive analysis, where drug potency, the timing of therapy initiation, drug combinations, variability in systemic and local drug exposure and short- and long-term toxicities represent fundamental factors for the rational identification of candidates and prioritization of clinical investigations. Although the identification of SARS-CoV-2 therapeutics is a priority, rigorous and transparent methodologies are crucial to ensure that accelerated research programmes result in high-quality and reproducible findings.
?:creator
?:doi
?:doi
  • 10.1093/jac/dkaa272
?:journal
  • J_Antimicrob_Chemother
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/f8abb6169ec86bb752465057a6eb159787ef8776.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7337743.xml.json
?:pmcid
?:pmid
?:pmid
  • 32591771.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics
?:type
?:year
  • 2020-06-26

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/4c0t3w29>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/4c0t3w29>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all